Does a left ventricular ejection fraction of 10–15% indicate both systolic (heart failure with reduced ejection fraction) and diastolic (heart failure with preserved ejection fraction) heart failure?

LVEF 10-15% Indicates Heart Failure with Reduced Ejection Fraction (Systolic Heart Failure), NOT Diastolic Heart Failure

An LVEF of 10-15% definitively represents heart failure with reduced ejection fraction (HFrEF), which is severe systolic dysfunction—this is NOT diastolic heart failure or HFpEF. 1

Understanding the Classification

The 2016 ESC Guidelines clearly define the heart failure spectrum based on LVEF 1:

• HFrEF (Heart Failure with Reduced EF): LVEF <40% - this is your patient
• HFmrEF (Heart Failure with Mid-range EF): LVEF 40-49%
• HFpEF (Heart Failure with Preserved EF): LVEF ≥50%

Your patient with LVEF 10-15% falls far below the 40% threshold and represents severe systolic dysfunction.

Critical Clarification: Why This Is NOT Diastolic Heart Failure

The terminology can be confusing, but here's what you need to understand:

• "Systolic heart failure" = HFrEF (what your patient has)
• "Diastolic heart failure" = HFpEF (preserved EF ≥50%)

However, most patients with HFrEF also have diastolic dysfunction present 1. This means your patient likely has BOTH systolic AND diastolic dysfunction occurring simultaneously, but the classification is based on the dominant problem—which is clearly systolic failure given the severely reduced EF.

The 2016 ESC Guidelines explicitly state: "most patients with HFrEF (previously referred to as 'systolic HF') also have diastolic dysfunction" 1. This doesn't make it "diastolic heart failure"—it remains classified as HFrEF because the primary pathophysiology is systolic dysfunction.

Clinical Implications for LVEF 10-15%

This represents severe, advanced systolic heart failure requiring aggressive guideline-directed medical therapy 2:

Immediate Pharmacologic Management

First-line therapy must include 2:

• ACE inhibitors (or ARBs if intolerant)
• Beta-blockers (bisoprolol, metoprolol succinate, carvedilol, or nebivolol)
• Mineralocorticoid receptor antagonists (aldosterone antagonists)
• SGLT2 inhibitors (based on contemporary evidence)

Device Therapy Considerations

With LVEF this severely reduced, evaluate for 2:

• ICD candidacy: LVEF <30-35% meets criteria for primary prevention of sudden cardiac death
• Cardiac resynchronization therapy (CRT): If LVEF <35% with QRS ≥150ms or 120-149ms with mechanical dyssynchrony

Monitoring Requirements

Close monitoring of 2:

• Renal function and potassium (especially with ACE inhibitors and aldosterone antagonists)
• Volume status requiring diuretics for symptom management
• Consider natriuretic peptide-guided therapy in younger patients (<75 years)

Common Pitfall to Avoid

Do not confuse the presence of diastolic dysfunction in a patient with HFrEF with the diagnosis of "diastolic heart failure" (HFpEF). These are distinct entities. Your patient's LVEF of 10-15% unequivocally places them in the HFrEF category, where evidence-based therapies have proven mortality benefit 1.

The distinction matters because only HFrEF has robust evidence for therapies that reduce both morbidity and mortality 1. HFpEF management focuses primarily on symptom control and comorbidity management with less definitive mortality benefit from specific therapies 2.